Cyclo Therapeutics Inc
NASDAQ:CYTH

Watchlist Manager
Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc
NASDAQ:CYTH
Watchlist
Price: 99 USD 12.08%
Market Cap: 2.1B USD

Intrinsic Value

CYTH doesn't have a meaningful market cap.

The intrinsic value of one CYTH stock under the Base Case scenario is 709.64 USD. Compared to the current market price of 99 USD, Cyclo Therapeutics Inc is Undervalued by 86%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CYTH Intrinsic Value
709.64 USD
Undervaluation 86%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Cyclo Therapeutics Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about CYTH?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CYTH valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Cyclo Therapeutics Inc.

Explain Valuation
Compare CYTH to

Fundamental Analysis

Cyclo Therapeutics Inc
NASDAQ:CYTH
US
Biotechnology
Market Cap
2.1B USD
IPO
Feb 27, 2004
US
Biotechnology
Market Cap
2.1B USD
IPO
Feb 27, 2004
Price
$
$
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CYTH?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cyclo Therapeutics Inc

Current Assets 3.3m
Cash & Short-Term Investments 928k
Receivables 187.7k
Other Current Assets 2.1m
Non-Current Assets 2m
PP&E 46.6k
Other Non-Current Assets 2m
Current Liabilities 18.7m
Accounts Payable 5.8m
Accrued Liabilities 751.9k
Short-Term Debt 12.2m
Non-Current Liabilities 7.1k
Other Non-Current Liabilities 7.1k
Efficiency

Free Cash Flow Analysis
Cyclo Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Cyclo Therapeutics Inc

Revenue
870.7k USD
Cost of Revenue
-76.2k USD
Gross Profit
794.5k USD
Operating Expenses
-25.5m USD
Operating Income
-24.7m USD
Other Expenses
-122.8k USD
Net Income
-24.8m USD
Fundamental Scores

CYTH Profitability Score
Profitability Due Diligence

Cyclo Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

44/100
Profitability
Score

Cyclo Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

CYTH Solvency Score
Solvency Due Diligence

Cyclo Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Positive Net Debt
37/100
Solvency
Score

Cyclo Therapeutics Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYTH Price Targets Summary
Cyclo Therapeutics Inc

There are no price targets for CYTH.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Cyclo Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CYTH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CYTH Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one CYTH stock?

The intrinsic value of one CYTH stock under the Base Case scenario is 709.64 USD.

Is CYTH stock undervalued or overvalued?

Compared to the current market price of 99 USD, Cyclo Therapeutics Inc is Undervalued by 86%.

Back to Top